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Abstract
Background: To date, there has been no studies to evaluate the incidence of Crohn’s disease in systemic sclerosis
patients. The goals of this study were to evaluate the incidence of Crohn’s disease and its relationship with sex and
age in patients with systemic sclerosis.
Methods: We enrolled patients with systemic sclerosis and controls from Taiwan’s Registry of Catastrophic Illness
Database and National Health Insurance Research Database. Every systemic sclerosis patient was matched to at
most three controls by sex, age, month and year of initial diagnosis of systemic sclerosis. The standardized
incidence ratio (SIR) of Crohn’s disease in systemic sclerosis patients, and 95 % confidence interval (95 % CI) were
calculated. Cox hazard regression was used to calculate the hazard ratio (HR).
Results: The study enrolled 2,829 patients with systemic sclerosis and 8,257 controls. Male and female patients
with systemic sclerosis both had lower rates of incident Crohn’s disease (SIR: 0.18, 95 % CI = 0.05–0.62; SIR: 0.10,
95 % CI = 0.05–0.21, respectively). The risk of incident Crohn’s disease in systemic sclerosis was still lower than in
controls when we stratified the patients according to their ages. In Cox hazard regression, the hazard rates of
Crohn’s disease were lower in systemic sclerosis patients after adjusting for genders and ages (HR: 0.12, 95 %
CI = 0.06–0.21, p < 0.001).
Conclusions: Systemic sclerosis is associated with decreased incidence of, irrespective of sex and age of the
patients.
Background
Systemic sclerosis is a multisystem autoimmune disease
characterized by endothelial dysfunction, widespread ob-
literative vasculopathy, and excessive collagen deposition
in affected organs, culminating in tissue fibrosis [1]. Im-
munologically, it is associated with autoantibodies [1].
Clinically, it is divided into a limited form and a diffuse
form [1]. Besides its own morbidity, there is an increas-
ingly number of reports showing coexisting medical
diseases such as systemic lupus erythematosus [2] and
autoimmune thyroid disease associated with systemic
sclerosis [3]. However, there are also studies pointing to a
reduced risk of autoimmune diseases, such as inflammatory
bowel disease, in association with systemic sclerosis [4].
Crohn’s disease is a type of inflammatory bowel disease.
Several studies have varied conclusions about whether sys-
temic sclerosis implies a greater risk of Crohn’s disease.
For example, in one study [5], the risk of Crohn’s disease
differed across two databases in systemic sclerosis patients.
Another study showed reduced risk of inflammatory
bowel disease in the family members of patients with sys-
temic sclerosis [4]. Besides conflicting results in the litera-
ture, previous studies focused on the prevalence of Crohn’s
disease instead of the incidence of Crohn’s disease. In
addition, the relationship of age and sex in regards to
Crohn’s disease incidence in systemic sclerosis needs to be
further elucidated. Thus we conducted this study to explore
the incidence of Crohn’s disease and its relationship with
sex and age in systemic sclerosis patients.
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In Taiwan, the Ministry of Health and Welfare imple-
mented the National Health Insurance (NHI) program
in 1995. Since then, 99.6 % of the total population in
Taiwan has enrolled in the NHI [6]. The Ministry also
established the NHI database which has collected the
dates of birth, the diagnoses of patients, the dates of
doctor’s visits, sex, and other related information of
patients. Numerous studies utilize this database to survey
the risk of comorbidities in diseases including systemic
sclerosis and Crohn’s disease [7, 8].
The NHI medical claims database is administered by
Taiwan’s National Health Research Institutes (NHRI). The
NHRI provided National Health Insurance Research Data-
base (NHIRD) 1,000,000 random subjects for this study,
which represents approximately five percent of Taiwan’s
population. A systematic, random sampling method was
used to build this representative database. There were 23
million patients in the original claim database, with one
specific corresponding identification number for each
person. A random number generator generated 1,000,000
random numbers. After eliminating duplicate values, we
used these random numbers to include persons with corre-
sponding identification numbers in NHIRD. The process
was repeated until 1,000,000 subjects were enrolled in
NHIRD. This population is representative of Taiwan’s
national population with respect to age, sex, and other
characteristics. For this study, we obtained a longitu-
dinal cohort from the NHIRD from 1998 to 2011. An-
other database acquired from the NHRI was the
Registry of Catastrophic Illness that included informa-
tion of all 23 million Taiwanese citizens. According to
Taiwan’s regulations, insured persons with major dis-
eases such as systemic sclerosis and Crohn’s disease
could apply for a catastrophic illness certificate for ex-
emption from copayment. For Crohn’s disease to be reg-
istered in the Registry of Catastrophic Illness database, the
attending physician must submit information about the
clinical diagnosis, laboratory results, endoscopic findings,
pathological reports as well as the possible image studies to
register the patient’s diagnosis of Crohn’s disease, as well as
for excluding intestinal tuberculosis. For systemic sclerosis
to be registered in the Registry of Catastrophic Illness data-
base, patients must fullfill 1980 Ammerican College of
Rheumatology criteria. These applications for catastrophic
illness certificates were reviewed by related specialists and
justified by a meticulous examination of the medical re-
cords as well as related exam results. Because the NHRI
releases these two databases with scrambled identifica-
tion numbers, it is impossible to identify patients from
these databases. No written informed consent was neces-
sary in this situation according to Taiwan’s regulations.
Thus the analysis of the databases was exempt from the
ethical approval by the Institutional Review Board of
Kaohsiung Medical University Hospital (KMUH-IRB-EX-
EMPT-20140007).
Study sample
The NHI database diagnosis coding mirrors the Inter-
national Classification of Diseases, Ninth Revision
(ICD-9), Clinical Modification diagnosticcriteria. We
used Registry of Catastrophic Illness to identify pa-
tients with systemic sclerosis (ICD-9: 7101) diagnosed
in 1998 to 2011 because patients diagnosed with sys-
temic sclerosis before this period might already have
systemic sclerosis with unknown duration. We ex-
cluded patients with Crohn’s disease (ICD-9: 555) diag-
nosed before systemic sclerosis or within 1 year after
diagnosis of systemic sclerosis. The reason behind ex-
cluding patients with Crohn’s disease diagnosed within
1 year after diagnosis of systemic sclerosis is to ensure that
Crohn’s disease diagnosis came after their diagnosis of sys-
temic sclerosis. Only patients older than 20 years old were
included in our analysis. We used NHIRD to collect the
control group consisting of patients without systemic
sclerosis. Control patients could have other diseases
except systemic sclerosis, such as glaucoma, hyperlip-
idemia, and so on. Subjects with preexisting Crohn’s dis-
ease prior to enrollment or within one year after
enrollment were excluded. Each systemic sclerosis patient
was matched to at most three control patients by gender,
year of birth (within 2 years of birthdates of cases), and the
time of first diagnosis at enrollment. The goal of this
matching was to ensure that there were no significant
difference in sex, age, and follow-up time between
study subjects and controls.
The endpoint and follow up
Follow-up started on the date of first diagnosis of systemic
sclerosis in the systemic sclerosis group and on the same
date in the matched control group and ended on the date
of diagnosis of Crohn’s disease (identified with ICD-9: 555
in the Registry of Catastrophic Illness database), death,
transfer out, or the end of 2011.
The Incidence of Crohn’s disease and Standardized
Incidence Ratio (SIR)
We estimated the incidence of Crohn’s disease per 1000
person-years in patients with systemic sclerosis and control
subjects, and calculated the age-adjusted standardized inci-
dence ratio (SIR), which is the ratio between observed
number of Crohn’s disease and expected number of Crohn’s
disease, calculated as observed cases divided by expected
cases for each age group. The well-described method of
95 % confidence intervals (95 % CI) estimation [9] was
used. We also defined the onset age of Crohns’ disease
as the age at which the patient received the diagnosis of
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Crohn’s disease in the Registry of Catastrophic Illness
database.
Statistical analysis
Age-adjusted SIR of Crohn’s disease in different groups of
systemic sclerosis was calculated. We used Student’s t-test
to compare the onset age of Crohn’s disease between differ-
ent groups of patients. We used the Kaplan-Meier analysis
to estimate the event-free probability of Crohn’s disease
after enrollment. The log-rank test was used to compare
among different groups of patients. We utilized Cox hazard
regression to calculate the hazard ratio (HR) and 95 % con-
fidence intervals (95 % CI) for incident Crohn’s disease in
patients with systemic sclerosis compared to controls. All
statistical operations were performed using SPSS (v19.3)
after mining the national outpatient records using the PERL
(v5.8).
Results
For the analysis of risk of Crohn’s disease, 2,829 patients
with systemic sclerosis and 8,257 controls were included.
All patients were gathered from the outpatient database
from 1998 to 2011. The mean ages of case and control
groups were 49.27 ± 14.63 and 49.44 ± 14.57 years, re-
spectively (Table 1). The age distribution was not statis-
tically different between systemic sclerosis patients and
controls (p > 0.05).
Reduced risk of Crohn’s disease in systemic sclerosis
A total of 332 cases of incidental Crohn’s disease were
diagnosed during the follow-up period, 11 in the case
group and 321 in the control group (Table 2). The inci-
dence of Crohn’s disease was estimated to be 0.56 cases
per 1000 person-years among systemic sclerosis cases
during the 1998–2011 period; controls had an incidence
of 4.82 cases per 1000 person-years. Age-adjusted SIR of
Crohn’s disease was 0.12 (95 % CI = 0.06–0.22), which
suggests that patients with systemic sclerosis had 0.12
times of the risk of developing Crohn’s disease compared
to controls after adjusting for age. Furthermore, the risk
of incident Crohn’s disease in systemic sclerosis patients
was lower than controls when stratified based on their
respective ages.
We then stratified patients according to their sex.
There were a total of 514 male patients with systemic
sclerosis and 1,448 male controls (Table 3), 2,315 female
patients with systemic sclerosis and 6,809 female con-
trols (Table 4).
A total of 65 cases of incidental Crohn’s disease in male
patients were diagnosed during the follow-up period, 3 in
the case group and 62 in the control group. The incidence
of Crohn’s disease was estimated to be 0.97 cases per 1000
person-years among male systemic sclerosis cases during
the 1998–2011 period; male controls had an incidence of
5.47 cases per 1000 person-years (Table 3). Age-adjusted
SIR of Crohn’s disease was 0.18 (95 % CI = 0.05–0.62),
which suggests male patients with systemic sclerosis had
0.18 times of the risk of developing Crohn’s disease com-
pared to male controls after adjusting for age. Reduced
risk of Crohn’s disease only existed in patients older than
50 years due to a small sample size in male patients youn-
ger than 50 years.
A total of 267 cases of incidental Crohn’s disease in fe-
male patients were diagnosed during the follow-up
period, 8 in the case group and 259 in the control group.
The incidence of Crohn’s disease was estimated to be
0.48 cases per 1000 person-years among female systemic
sclerosis cases during the 1998–2011 period; female con-
trols had an incidence of 4.68 cases per 1000 person-
years (Table 4). Age-adjusted SIR of Crohn’s disease was
0.10 (95 % CI = 0.05–0.21), which suggests that female
patients with systemic sclerosis had 0.10 times of the
risk of developing Crohn’s disease compared to female
controls after adjusting for age. Furthermore, reduced
risk of Crohn’s disease in systemic sclerosis was present
when stratified based on their respective ages.
Table 1 The age distribution in baseline and follow-up time of systemic sclerosis patients and the controls
Systemic sclerosis Controls
(n = 2829) (n = 8257)
Age(years; mean ± SD) 49.27 ± 14.63 49.44 ± 14.57
Age group at enrollment(years) n (%) Person-yearsa n (%) Person-years
> = 20, <30 315 (11.13) 2105.67 897 (10.86) 6676.17
> = 30, <40 459 (16.22) 3596.42 1301 (15.76) 11209.67
> = 40, <50 697 (24.64) 5448.33 2067 (25.03) 18276.25
> = 50, <60 681 (24.07) 4562.83 1975 (23.92) 15573.33
> = 60, <70 427 (15.09) 2607.00 1294 (15.67) 9607.75
> = 70, <80 220 (7.78) 1161.83 636 (7.70) 4753.08
> = 80 30 (1.06) 118.67 87 (1.05) 532.50
SD standard deviation; a:The total follow-up person-years
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The onset age of Crohn’s disease
We analyzed the onset age of Crohn’s disease according to
sex. In male patients, the mean onset age of Crohn’s disease
in systemic sclerosis patients and control groups were
50.22 ± 10.35 years and 57.11 ± 15.04 years (data not
shown), and not significantly different (p = 0.438). In fe-
male patients, the mean onset age of Crohn’s disease in
systemic sclerosis patients and control groups were
46.89 ± 13.57 years and 53.10 ± 14.38 years (data not
shown), and not significantly different (p = 0.229).
The hazard ratio of Crohn’s disease in systemic sclerosis
patients
We then used Cox hazard regression to calculate the
hazard ratio of Crohn’s disease among all participants
after adjusting for age, sex, and systemic sclerosis. Sys-
temic sclerosis (HR = 0.12, 95 % CI = 0.06–0.21, p < 0.001)
was significantly associated with reduced incident Crohn’s
disease after adjusting for age and sex.
A comparison of the risk of Crohn’s disease between sys-
temic sclerosis patients and control patients is shown in
Fig. 1. The probability of developing Crohn’s disease were
lower in male systemic sclerosis patients than in male con-
trols (p < 0.001). Female systemic sclerosis patients also had
lower probability of developing Crohn’s disease compared
to female controls (p < 0.001).
Discussion
In this study, we utilized a retrospective cohort study to
demonstrate significantly reduced incidence of Crohn’s
disease in patients with systemic sclerosis, irrespective of
gender and age of the patient. The age of diagnosis of
Crohn’s disease was not different between systemic
sclerosis patients and controls. To our knowledge, this
was the first study to demonstrate reduced incidence
of Crohn’s disease in systemic sclerosis. Past studies
were discrepant in the relationship between systemic
sclerosis and Crohn’s disease. For example, one study in
French [4] noted decreased prevalence of inflammatory
bowel disease in family members of systemic sclerosis
patients. However, the diagnosis of Crohn’s disease was
identified by questionnaire rather than validated databases,
as in our study. Another study [5] found conflicting results
about risk of Crohn’s disease in systemic sclerosis across
two different healthcare databases. Aside from unrepresen-
tational sample, rather short follow-up time (2 years) was
present. Furthermore, no information about incidence was
available from these two studies.
The reason behind this phenomenon was not immedi-
ately clear from this epidemiology study. There were no
studies to explore the protective effects of systemic
sclerosis on Crohn’s disease. However, genome-wide as-
sociation studies and immunologic studies implicated
genetic and immunologic factors in the two diseases.
Table 2 Age-adjusted standardized incidence ratio of Crohn’s disease in scleroderma patients stratified by age
Systemic sclerosis Control Incidence Ratio 95 % CI
(n = 2829) (n = 8257)
Age at diagnosis Observed(Inc)a Observed(Inc)
> = 20, <30 1 (0.47) 39 (5.84) 0.08 0.01–0.58
> = 30, <40 4 (1.11) 51 (4.55) 0.24 0.09–0.66
> = 40, <50 2 (0.37) 77 (4.21) 0.09 0.02–0.37
> = 50, <60 3 (0.66) 72 (4.62) 0.14 0.04–0.44
> = 60 1 (0.26) 82 (5.51) 0.05 0.01–0.36
Total 11 (0.56) 321 (4.82) 0.12 0.07–0.22
Age adjusted standardized incidence ratio 0.12 0.06–0.22
95 % CI 95 % confidence interval; a:observed numbers of new diagnosed Crohn’s disease (incidence per 1000 person-years)
Table 3 Age-adjusted standardized incidence ratio of Crohn’s disease in male scleroderma patients stratified by age
Systemic sclerosis Control Incidence Ratio 95 % CI
(n = 514) (n = 1448)
Age at diagnosis Observed(Inc)a Observed(Inc)
> = 20, <40 1 (1.31) 16 (7.03) 0.19 0.03–1.43
> = 40, <50 1 (1.59) 9 (4.21) 0.38 0.05–2.97
> = 50 1 (0.59) 37 (5.35) 0.11 0.02–0.79
Total 3 (0.97) 62 (5.47) 0.18 0.06–0.57
Age adjusted standardized incidence ratio 0.18 0.05–0.62
95 % CI 95 % confidence interval; a:observed numbers of new diagnosed Crohn’s disease (incidence per 1000 person-years)
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The frequency of the HLA-DR3 serotype was higher in
patients of systemic sclerosis [10, 11] but lower in
Crohn’s disease [12]. On the other hand, the presence of
the HLA-DR7 serotype was correlated with decreased
risk of systemic sclerosis [13], but was associated with
higher risk of Crohn’s disease [12]. It was hypothesized
that the specific HLA may determine the targeting of
particular antigens [14], resulting in specific associations
with different diseases.
Besides HLA, protein tyrosine phosphatase non-receptor
type 22 (PTPN22) was implicated in both systemic sclerosis
and Crohn’s disease. Previous study showed PTPN22
C1858T (R620W), a gain of function [15], was correlated
with higher risk of systemic sclerosis [16–20], but reduced
risk of Crohn’s disease [18, 21].
Past studies showed reduced PTPN22 expression in the
gastrointestinal tract of patients with Crohn’s disease [22],
and PTPN22 deficiency caused: increased secretion of
interleukin-6 (IL-6) and IL-8, increased activation of p38
and c-Jun N-terminal kinase (JNK), increased phosphoryl-
ation of nuclear factor κB (NF-kB) p65, and increased au-
tophagy, all which could lead to prolonged survival of
activated macrophage and promote inflammatory condition
in Crohn’s disease [23]. Thus PTPN22 C1858T polymorph-
ism, which is associated with systemic sclerosis susceptibil-
ity, reduced the risk of Crohn’s disease.
Table 4 Age-adjusted standardized incidence ratio of Crohn’s disease in female scleroderma patients stratified by age
Systemic sclerosis Control Incidence Ratio 95% CI
(n=2315) (n=6809)
Age at diagnosis Observed(Inc)a Observed(Inc)
>=20, <30 1 (0.56) 35 (6.07) 0.09 0.01–0.65
>=30, <40 3 (0.95) 39 (3.96) 0.24 0.07–0.78
>=40, <50 1 (0.21) 68 (4.21) 0.05 0.01–0.36
>=50, <60 2 (0.53) 57 (4.60) 0.12 0.03–0.49
>=60 1 (0.33) 60 (5.38) 0.06 0.01–0.44
Total 8 (0.48) 259 (4.68) 0.10 0.05–0.20
Age adjusted standardized incidence ratio 0.10 0.05–0.21
95 % CI 95 % confidence interval; a:observed numbers of new diagnosed Crohn’s disease (incidence per 1000 person-years)
Fig. 1 Kaplan-Meier plot of Crohn’s disease for patients with systemic sclerosis and controls. a For male systemic sclerosis patients and male controls
(p< 0.001, estimated by the log-rank test). b For female systemic sclerosis patients and female controls (p< 0.001, estimated by the log-rank test)
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In addition to HLA and PTPN22, immunologic factors
were also involved. T-bet, encoded by the TBX21 gene, was
involved in systemic sclerosis and Crohn’s disease. In the
animal model of systemic sclerosis, T-bet knockout mice
were associated with increased susceptibility to skin scler-
osis [24]. TBX21 rs11650354 was also a susceptibility factor
in systemic sclerosis [25]. On the contrary, enhanced T-bet
expression in active Crohn’s disease intestine was demon-
strated [26]. Higher T-bet expression in peripheral blood
mononuclear cells in Crohn’s disease was also noted [27].
T-bet deficiency protects mice from colitis, but overexpres-
sion of T-bet accelerates colitis [28]. T-bet up-regulation
established immunopathology in Crohn’s disease [29]. Thus
T-bet deficiency in systemic sclerosis may be a cause in
reducing the risk of Crohn’s disease.
There were some limitations in this study. First, antibi-
otics, nonsteroidal antiinflammatory drugs (NSAIDs),
smoking, and appendectomy were not adjusted in this
study. However, prednisolone, azathioprine, cyclophospha-
mide, mycophenolate mofetil, methotrexate, and penicilla-
mine, which were used to treat patients with systemic
sclerosis, were associated with infection requiring antibi-
otics treatment [30–33]. Antibiotics increased rather than
decreased incidence of Crohn’s disease [34]. NSAIDs,
which were used in in systemic sclerosis, increased in-
stead of decreasing subsequent Crohn’s disease [35]. In
addition, although smoking and appendectomy increased
risk of Crohn’s disease in western contries [36, 37], smoking
and appendectomy were not risk factors for Crohn’s disease
in Asia [36, 38]. Thus antibiotics, nonsteroidal antiin-
flammatory drugs (NSAIDs), smoking, and appendec-
tomy couldn’t explain the protective effects exerted by
systemic sclerosis on Crohn’s disease. Second, systemic
sclerosis was divided into a limited form and a diffuse
form. However, both shared the same ICD-9 code. It
was noted in previous studies that different disease sub-
types implied different clinical courses [39]. Patients
couldn’t be stratified further based on systemic sclerosis
subtypes—limited form and diffuse form—because patients
with different subtypes had similar ICD-9 diagnosis code in
the Registry of Catastrophic Illness database. Furthermore,
information about family history and diet style was not
available from the national health insurance database.
These common limitations have been noted in the
claim-based dataset [8].
Conclusion
In conclusion, this was the first nationwide population-
based study to demonstrate reduced incidence of Crohn’s
disease in patients of systemic sclerosis. Current literature
shed some light on some potential causes behind this
phenomenon, including HLA, PTPN22, and T-bet. How-
ever, further studies are necessary to clarify the risk of
Crohn’s disease in systemic sclerosis in regards to different
subtypes of scleroderma.
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